Maxim Group Reiterates Buy Rating for BeyondSpring Inc. (BYSI)
“BeyondSpring announced that the enrollment of the first patient in China for Plinabulin (P2/3 trial) in the Harbin Medical University Cancer Hospital in Harbin, China. This news follows other recent positives which include: ○ Positive Regulatory Reforms in China. The State Council of China announced on October 8, 2017 regulatory reforms, which could translate into an accelerated review (shorter time to the marketplace). Our current timeline assumes approvals and launch in China by 2020. This news is consistent with what we are hearing amongst our other covered companies in China such as BeiGene (BGNE – $80.01 – Buy). ○ Two China-based Grants. The first from the city government of Dalian, China. The second from the Dalian Economic Development Park. Conclusion: Plinabulin could become the standard of care for chemo patients as a prophylactic treatment for the CIN indication alone. The market opportunity extends beyond the $8B biologics market and could be upwards of $30B.”,” Maxim Group’s analyst wrote.
A number of other brokerages have also issued reports on BYSI. Zacks Investment Research lowered shares of BeyondSpring from a hold rating to a sell rating in a research note on Monday, July 3rd. HC Wainwright restated a buy rating and issued a $50.00 target price on shares of BeyondSpring in a research note on Monday, August 21st. Finally, Rodman & Renshaw upped their target price on shares of BeyondSpring from $43.00 to $50.00 and gave the company a buy rating in a research note on Friday, July 14th.
BeyondSpring (BYSI) opened at 33.84 on Friday. BeyondSpring has a one year low of $16.55 and a one year high of $48.49. The stock’s market cap is $773.04 million. The firm’s 50 day moving average price is $37.00 and its 200 day moving average price is $35.81.
COPYRIGHT VIOLATION NOTICE: This news story was originally published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The correct version of this news story can be accessed at https://theolympiareport.com/2017/10/31/maxim-group-reiterates-buy-rating-for-beyondspring-inc-bysi.html.
An institutional investor recently bought a new position in BeyondSpring stock. Tanaka Capital Management Inc. bought a new stake in BeyondSpring Inc. (NASDAQ:BYSI) during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 21,322 shares of the company’s stock, valued at approximately $914,000. BeyondSpring makes up 2.1% of Tanaka Capital Management Inc.’s investment portfolio, making the stock its 16th biggest position. Tanaka Capital Management Inc. owned approximately 0.10% of BeyondSpring as of its most recent filing with the SEC. Institutional investors own 1.23% of the company’s stock.
BeyondSpring Company Profile
BeyondSpring Inc is a global clinical-stage biopharmaceutical company. The Company is focused on the development of cancer therapies. The Company is engaged in advancing its lead product, Plinabulin, into a Phase II/III clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase II/III clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia, and a Phase III clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC).
Receive News & Ratings for BeyondSpring Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeyondSpring Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.